EUVIMEDEUVIMED entdecken
Crossref

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review

Mehmet Emin Demir, Zafer Ercan, Bülent Erdoğan

Journal of Cardiology & Cardiovascular Surgery · 2023

DOI: 10.51271/jccvs-0003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiology & Cardiovascular Surgery, 2023. Verfasst von Mehmet Emin Demir und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium-glucose co-transporter-2 inhibitors are novel antihyperglycemic agents which have crucial effects on the heart and kidneys beyond their glucose-lowering features. Their main clinical benefits have been reported in individuals with type 2 diabetes mellitus, chronic kidney disease, heart failure, and proteinuria. However, adverse reactions (euglycemic ketoacidosis, kidney dysfunction, genital and urinary tract infections, hypovolemia, etc) remain to be the main object of the debate regarding their use. The recruited data have encouraged clinicians to use those medicines in individuals who fit the indications for use.

Zitieren

APA

Demir, M. E., Ercan, Z., & Erdoğan, B. (2023). Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review. Journal of Cardiology & Cardiovascular Surgery. https://doi.org/10.51271/jccvs-0003

Vancouver

Demir ME, Ercan Z, Erdoğan B. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review. Journal of Cardiology & Cardiovascular Surgery. 2023. doi:10.51271/jccvs-0003

BibTeX
@article{Demir2023,
  author = {Demir, Mehmet Emin and Ercan, Zafer and Erdoğan, Bülent},
  title = {Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a brief review},
  journal = {Journal of Cardiology & Cardiovascular Surgery},
  year = {2023},
  doi = {10.51271/jccvs-0003}
}
Kostenlos starten →